|Awarded On||February 15, 2023|
|Title||Screen, Treat, or Prevent (STOP) Hepatocellular Cancer-Hepatitis C (HCC-HCV): Expansion to All Adults|
|Award Mechanism||Cancer Screening and Early Detection|
|Institution/Organization||The University of Texas Southwestern Medical Center|
|Principal Investigator/Program Director||Mamta Jain|
|Cancer Sites||Gallbladder, Liver and Intrahepatic Bile Duct|
*Pending contract negotiation
Need: Hepatocellular cancer (HCC) is the fastest growing cancer in Texas. The age-adjusted incidence of liver cancer in Texas is the highest in the U.S. The majority of HCC is due to viral hepatitis, primarily hepatitis C (HCV) in the US and hepatitis B virus (HBV) globally. HCV is curable and HBV is a vaccine-preventable disease. To reduce HCC burden, we are targeting counties in North and South Texas with high HCC incidence and significant need to increase prevention through HCV and HBV screening, immunization, and treatment. Recent changes in national guidelines recommend screening for HCV in all adults 18-79 years old and universal hepatitis B vaccination for adults 19-59 years old to re...